Imunopharm

Developer of gene and cell therapies to treat malignant tumors

placeHaidian, Beijing, China calendar_todayFounded 2015 groups100 employees language imunopharm.com

Social engagement

Social engagement: 241 social following, 9 posts in the last 12 months — above the industry median.

Investor mix

6 investors on record.

Investor typeCountShare
Venture capital350%
Other / undisclosed350%

Recent activity

26 Jan 2026
Milestone
regulatory
12 Jan 2026
Milestone
regulatory
27 Dec 2025
Milestone
regulatory
Coming soon